ETOP IBCSG PARTNERS FOUNDATION

Name

ETOP IBCSG PARTNERS FOUNDATION

Legal name

ETOP IBCSG Partners Foundation

Website

https://etop-eu.org

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Clinical Research Services

NAICS

Other Scientific and Technical Consulting Services (54169)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Membership Organizations (8600)

akta.pro primary industry

Clinical Trial Site Operations & Study Coordination (HLAGACAE)

akta.pro secondary industries

Site Data Management Support (EDC/Source/SDV Readiness) (HLAGACAL), Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA), Site & Investigator Platforms (Site Payments, Feasibility, Activation) (HLACAOAJ)

Keywords

• Clinical trial management
• Translational research
• Thoracic oncology research
• Cancer research foundation
• Biomedical research services

Headquarters

HQ city

Bern

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Revenue model

1. Donations and Research Funding: As a foundation, ETOP IBCSG Partners operates primarily through donations and research funding to sponsor and manage clinical trials in thoracic malignancies. The organization conducts translational research projects either within clinical trials or as independent epidemiology projects.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

ETOP IBCSG Partners Foundation is a Swiss non-profit research foundation that sponsors and manages multi-center clinical trials and translational research projects in thoracic malignancies (lung cancer, mesothelioma, and related cancers). It operates the ETOPdata platform for clinical trial data management, runs named translational research programs (Lungscape, Mesoscape, Lungscope, Smallscope), and delivers educational resources including conferences slide decks, live webinars, residential workshops, annual meetings, and the Lung Cancer Journal.

Product overview

ETOP IBCSG Partners Foundation is an organization that sponsors and manages clinical trials in thoracic malignancies. The foundation offers a portfolio of services including ETOP Clinical Trials (core clinical trial sponsorship and management) and Translational Research Projects (including Lungscape, Mesoscape, Lungscope, and Smallscope). Educational offerings include Conferences Slide Decks, ETOP Live Webinars, and ETOP Residential Workshops for young investigators. The foundation also organizes ETOP Annual Meetings and publishes the Lung Cancer Journal. All offerings are focused on advancing research and education in thoracic oncology.

Differentiator

Problem solved

Functional benefit

Products and services

• ETOP Clinical Trials Sponsorship and management of multi-center clinical trials in thoracic malignancies, including joint trials with partners such as EORTC (e.g., Phase III SPLENDOUR trial in advanced non-small cell lung cancer). Aimed at clinical investigators and research institutions.
• ETOP Translational Research Projects Translational and epidemiology research projects conducted within ETOP clinical trials or as independent studies, spanning lung cancer (Lungscape, Lungscope), mesothelioma (Mesoscape), and small cell lung cancer (Smallscope). Aimed at clinical investigators and translational researchers.
• ETOPdata A comprehensive clinical trial and translational research data management platform that enables the foundation to sponsor and manage trials and conduct translational research projects in thoracic malignancies. Used by investigators and collaborators participating in ETOP studies.
• Access to Biological Material for Research Provision of access to biological materials (tissue, blood, and other specimens) collected within ETOP clinical trials for use in investigator-led translational research. Targeted at clinical and translational researchers.
• ETOP Residential Workshops Multi-day residential workshops that support young investigators in thoracic oncology in developing clinical and translational research project proposals. Includes the 15th ETOP Residential Workshop scheduled for November 2026.
• ETOP Annual Meetings Annual meetings bringing together investigators and collaborators to inform them about ongoing ETOP activities and to enable active contribution by proposing future projects and trial ideas. The 2026 Annual Meeting is scheduled for 27-28 November in Zurich.
• ETOP Live Webinars Live virtual webinars presenting highlights of major thoracic oncology congresses (including AACR and ASCO) to the investigator community, supplementing the foundation's conference slide decks.
• ETOP Conferences Slide Decks Slide deck publications designed to highlight and summarize key findings in thoracic oncology from major congresses (e.g., AACR 2026, ASCO 2026), distributed to the investigator community.
• Lung Cancer Journal Journal publishing outcomes of ETOP projects and clinical trials in thoracic oncology, contributing peer-reviewed outputs to the lung cancer research field.

Quantifiable outcome

• Sponsors and manages an increasing number of clinical trials in thoracic malignancies

Named customers1 record

Segments1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered core.

• CHOSA OncologycoreStrategic or Co-development Partner · 19 March 2026CHOSA Oncology is collaborating with ETOP to present Platin-DRP biomarker data at the 2026 European Lung Cancer Congress. The data comes from a translational analysis of patients from the ETOP/EORTC Phase III SPLENDOUR trial in advanced non-small cell lung cancer. The 205-gene biomarker signature is designed to predict which patients are most likely to benefit from carboplatin and cisplatin treatment.
• EORTC (European Organisation for Research and Treatment of Cancer)coreStrategic or Co-development PartnerETOP partners with EORTC on the Phase III SPLENDOUR trial in advanced non-small cell lung cancer. This collaboration involves joint clinical trial sponsorship and translational research analysis, combining ETOP's thoracic oncology focus with EORTC's European cancer research infrastructure.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• EORTC (European Organisation for Research and Treatment of Cancer): European non-profit cancer research organization that sponsors multi-center clinical trials; jointly sponsors the Phase III SPLENDOUR trial with ETOP and shares an investigator-driven, foundation-based model focused on oncology.
• NRG Oncology: US-based NCI-sponsored cooperative group running multi-center oncology clinical trials; directly comparable in mission, governance, and investigator-network model, with overlapping thoracic disease committees.
• Alliance for Clinical Trials in Oncology: National Cancer Institute-sponsored clinical trials network conducting multi-institution oncology studies; comparable foundation/cooperative model for sponsoring thoracic and other solid tumor trials.
• IASLC (International Association for the Study of Lung Cancer): International professional society dedicated exclusively to lung cancer research, education, and policy; overlaps with ETOP's thoracic oncology focus, investigator community, and conference-based dissemination model.
• SOLTI (Solid Tumours): European academic cooperative group running breast and solid tumor clinical trials; directly comparable in size, mission, and investigator-driven trial sponsorship model, though with broader solid-tumor scope.
• IBCSG (International Breast Cancer Study Group): Cancer clinical trials cooperative group that is part of the merged ETOP IBCSG Partners Foundation; shares the same investigator-network, foundation structure, and multi-center trial sponsorship model as ETOP's thoracic oncology work.

Broad incumbents

• European Society for Medical Oncology (ESMO): Leading European professional oncology society; broader membership/educational remit than ETOP but overlapping thoracic oncology congress content, education programs, and investigator community.
• Cancer Research UK: Large UK-based cancer research charity funding clinical trials, translational science, and infrastructure across many tumor types; broader portfolio but overlapping trial sponsorship, translational projects, and donor-funding model.

Others

• CHOSA Oncology: Biomarker-focused precision oncology partner collaborating with ETOP on Platin-DRP translational analyses from the SPLENDOUR trial; comparable through its translational/biomarker work in lung cancer, though as a commercial partner rather than trial sponsor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/ETOP_IBCSG
• LinkedInlinkedin.com/company/european-thoracic-oncology-platform-etop-

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ETOP IBCSG PARTNERS FOUNDATION